Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

SAPHNELO shows strong sales growth and market potential for lupus treatment through 2034.

Market News
15 May 2026
Researchandmarkets.Com
View Source
Neutral
pluang ai news

SAPHNELO (Anifrolumab), a monoclonal antibody for moderate-to-severe systemic lupus erythematosus (SLE), demonstrates robust clinical efficacy by targeting type I interferon receptors. Approved in over 70 countries, it generated $483 million in sales in the first nine months of 2025, driven by a shift toward biologic therapies and high unmet medical needs in SLE. Despite a recent FDA request for more data on its subcutaneous form, AstraZeneca is actively addressing regulatory concerns. The market forecast through 2034 anticipates continued growth and expanded indications globally.

More News (AZN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App